Work

Supplementary Data from Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia

Year: 2023

Type: supplementary-materials

Abstract: Supplementary Methods.

DOI: 10.1158/1078-0432.22476794

Authors: Kendra Sweet, Rami Komrokji, Eric Padron, Christopher L. Cubitt, Joel G. Turner, Junmin Zhou, Alan F. List, David A. Sallman, Jana L. Dawson, Daniel M. Sullivan, Julio Chavez, Bijal D. Shah, Jeffrey E. Lancet

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361815354

Cites:

Cited by:

Related to: 10